Is the combinational administration of doxorubicin and glutathione a reasonable proposal?

  • 380 Accesses

  • 1 Citations

Abstract

The combinational administration of antioxidants and chemotherapeutic agents during conventional cancer treatment is among one of the most controversial areas in oncology. Although the data on the combinational usage of doxorubicin (DOX) and glutathione (GSH) agents have been explored for over 20 years, the duration, administration route, and authentic rationality have not yet been fully understood yet. In the current study, we systematically investigated the pharmacokinetics (PK) and pharmacodynamics (PD) with both in vivo and in vitro models to elucidate the influence of GSH on the toxicity and efficacy of DOX. We first studied the cardioprotective and hepatoprotective effects of GSH in Balb/c mice, H9c2, and HL7702 cells. We showed that coadministration of exogenous GSH (5, 50, and 500 mg/kg per day, intragastric) significantly attenuated DOX-induced cardiotoxicity and hepatotoxicity by increasing intracellular GSH levels, whereas the elevated GSH concentrations did not affect the exposure of DOX in mouse heart and liver. From PK and PD perspectives, then the influences of GSH on the chemotherapeutic efficacy of DOX were investigated in xenografted nude mice and cancer cell models, including MCF-7, HepG2, and Caco-2 cells, which revealed that administration of exogenous GSH dose-dependently attenuated the anticancer efficacy of DOX in vivo and in vitro, although the elevated GSH levels neither influenced the concentration of DOX in tumors in vivo, nor the uptake of DOX in MCF-7 tumor cells in vitro. Based on the results we suggest that the combined administration of GSH and DOX should be contraindicated during chemotherapy unless DOX has caused serious hepatotoxicity and cardiotoxicity.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

References

  1. 1.

    Block KI, Koch AC, Mead MN, Tothy PK, Newman RA, Gyllenhaal C. Impact of antioxidant supplementation on chemotherapeutic toxicity: a systematic review of the evidence from randomized controlled trials. Cancer Treat Rev. 2007;33:407–18.

  2. 2.

    Welch JS, Klco JM, Gao F, Procknow E, Uy GL, Stockerl-Goldstein KE, et al. Combination decitabine, arsenic trioxide, and ascorbic acid for the treatment of myelodysplastic syndrome and acute myeloid leukemia: a phase I study. Am J Hematol. 2011;86:796–800.

  3. 3.

    Bachleitnerhofmann T, Gisslinger B, Grumbeck E, Gisslinger H. Arsenic trioxide and ascorbic acid: synergy with potential implications for the treatment of acute myeloid leukaemia? Br J Haematol. 2015;112:783–6.

  4. 4.

    Werneke U. Risk management of nutritional supplements in chronic illness: the implications for the care of cancer and depression. Proc Nutr Soc. 2007;66:483–92.

  5. 5.

    Reczek CR, Chandel NS. Revisiting vitamin C and cancer: a high dose of vitamin C kills certain colon cancer cells. Science. 2015;350:1317–8.

  6. 6.

    Chandel NS, Ph D, Tuveson DA. Clinical implications of basic research. The promise and perils of antioxidants for cancer patients. N Engl J Med. 2014;371:177–8.

  7. 7.

    Ladas E, Kelly KM. The antioxidant debate. Explor(NY). 2010;6:75–85.

  8. 8.

    D’Andrea GM. Use of antioxidants during chemotherapy and radiotherapy should be avoided. CA Cancer J Clin. 2005;55:319–21.

  9. 9.

    Durken M, Herrnring C, Finckh B, Nagel S, Nielsen P, Fischer R, et al. Impaired plasma antioxidative defense and increased nontransferrin-bound iron during high-dose chemotherapy and radiochemotherapy preceding bone marrow transplantation. Free Radic Biol Med. 2000;28:887–94.

  10. 10.

    Conklin KA. Chemotherapy-associated oxidative stress: impact on chemotherapeutic effectiveness. Integr Cancer Ther. 2004;3:294–300.

  11. 11.

    Kennedy DD, Tucker KL, Ladas ED, Rheingold SR, Blumberg J, Kelly KM. Low antioxidant vitamin intakes are associated with increases in adverse effects of chemotherapy in children with acute lymphoblastic leukemia. Am J Clin Nutr. 2004;79:1029–36.

  12. 12.

    Kennedy DD, Ladas EJ, Rheingold SR, Blumberg J, Kelly KM. Antioxidant status decreases in children with acute lymphoblastic leukemia during the first six months of chemotherapy treatment. Pediatr Blood Cancer. 2005;44:378–85.

  13. 13.

    Cortésfunes H, Coronado C. Role of anthracyclines in the era of targeted therapy. Cardiovasc Toxicol. 2007;7:56–60.

  14. 14.

    Ramos DL, Gaspar JF, Pingarilho M, Gil OM, Fernandes AS, Rueff J, et al. Genotoxic effects of doxorubicin in cultured human lymphocytes with different glutathione S -transferase genotypes. Mutat Res. 2011;724:28–34.

  15. 15.

    Zhou F, Hao G, Zhang J, Zheng Y, Wu X, Hao K, et al. Protective effect of 23-hydroxybetulinic acid on doxorubicin-induced cardiotoxicity: a correlation with the inhibition of carbonyl reductase-mediated metabolism. Br J Pharmacol. 2015;172:5690–703.

  16. 16.

    Yeh ET, Tong AT, Lenihan DJ, Yusuf SW, Swafford J, Champion C, et al. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation. 2004;109:3122–31.

  17. 17.

    Kalender Y, Yel M, Kalender S. Doxorubicin hepatotoxicity and hepatic free radical metabolism in rats: the effects of vitamin E and catechin. Toxicology. 2005;209:39–45.

  18. 18.

    Zhao X, Tong N. Protective effects of berberine on doxorubicin-induced nephrotoxicity in mice. J Transl Med. 2012;10:120–8.

  19. 19.

    Li L, Takemura G, Li Y, Miyata S, Esaki M, Okada H, et al. Preventive effect of erythropoietin on cardiac dysfunction in doxorubicin-induced cardiomyopathy. Circulation. 2006;113:535–43.

  20. 20.

    Yeh YC, Lai HC, Ting CT, Lee WL, Wang LC, Wang KY, et al. Protection by doxycycline against doxorubicin-induced oxidative stress and apoptosis in mouse testes. Biochem Pharmacol. 2007;74:969–80.

  21. 21.

    Wang Y, Mei X, Yuan J, Lu W, Li B, Xu D. Taurine zinc solid dispersions attenuate doxorubicin-induced hepatotoxicity and cardiotoxicity in rats. Toxicol Appl Pharmacol. 2015;289:1–11.

  22. 22.

    Yoda Y, Nakazawa M, Abe T, Kawakami Z. Prevention of doxorubicin myocardial toxicity in mice by reduced glutathione. Cancer Res. 1986;46:2551–6.

  23. 23.

    Villani F, Galimberti M, Monti E, Piccinini F, Lanza E, Rozza A, et al. Effect of glutathione and N-acetylcysteine on in vitro and in vivo cardiac toxicity of doxorubicin. Free Radic Res. 1990;11:145–51.

  24. 24.

    Asakura T, Hashizume Y, Tashiro K, Searashi Y, Ohkawa K, Nishihira J, et al. Suppression of GST-P by treatment with glutathione–doxorubicin conjugate induces potent apoptosis in rat hepatoma cells. Int J Cancer. 2001;94:171–7.

  25. 25.

    Ge C, Bei C, Dong F, Fang Z, Zhang J, Na Y, et al. The down-regulation of SLC7A11 enhances ROS induced P-gp over-expression and drug resistance in MCF-7 breast cancer cells. Sci Rep. 2017;7:3791–9.

  26. 26.

    Labriola D, Livingston R. Possible interactions between dietary antioxidants and chemotherapy. Oncology. 1999;13:1011–2.

  27. 27.

    Gouazé V, Mirault ME, Carpentier S, Salvayre R, Levade T, Andrieuabadie N. Glutathione peroxidase-1 overexpression prevents ceramide production and partially inhibits apoptosis in doxorubicin-treated human breast carcinoma cells. Mol Pharmacol. 2001;60:488–96.

  28. 28.

    Yong LC, Brown CC, Schatzkin A, Dresser CM, Slesinski MJ, Cox CS, et al. Intake of vitamins E, C, and A and risk of lung cancer The NHANES I Epidemiologic Followup Study. Am J Epidemiol. 1997;146:231–43.

  29. 29.

    Männistö S, Smithwarner SA, Spiegelman D, Albanes D, Anderson K, Brandt PAVD, et al. Dietary carotenoids and risk of lung cancer in a pooled analysis of seven cohort studies. Cancer Epidemiol Biomark Prev. 2004;13:40–8.

  30. 30.

    Jenab M, Riboli E, Ferrari P, Friesen M, Sabate J, Norat T, et al. Plasma and dietary carotenoid, retinol and tocopherol levels and the risk of gastric adenocarcinomas in the European prospective investigation into cancer and nutrition. Br J Cancer. 2006;95:406–15.

  31. 31.

    Bjelakovic G, Nikolova D, Simonetti RG, Gluud C. Antioxidant supplements for preventing gastrointestinal cancers. Cochrane Database Syst Rev. 2004, 364(4):CD004183.

  32. 32.

    Fisher B, Redmond C, Legault-Poisson S, Dimitrov NV, Brown AM, Wickerham DL, et al. Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel Project B-16. J Clin Oncol. 1990;8:1005–18.

  33. 33.

    Nestal dMG, Vasconcelos FC, Delbue D, Mognol GP, Sternberg C, Viola JP, et al. Doxorubicin induces cell death in breast cancer cells regardless of survivin and XIAP expression levels. Eur J Cell Biol. 2013;92:247–56.

  34. 34.

    Olson RD, Boerth RC, Gerber JG, Nies AS. Mechanism of adriamycin cardiotoxicity: evidence for oxidative stress. Life Sci. 1981;29:1393–401.

  35. 35.

    Davies KJ, Doroshow JH. Redox cycling of anthracyclines by cardiac mitochondria. I. Anthracycline radical formation by NADH dehydrogenase. J Biol Chem. 1986;261:3060–7.

  36. 36.

    Sazuka Y, Tanizawa H, Takino Y. Effect of adriamycin on the activities of superoxide dismutase, glutathione peroxidase and catalase in tissues of mice. Jpn J Cancer Res. 1989;80:89–94.

  37. 37.

    Doroshow JH, Davies KJ. Redox cycling of anthracyclines by cardiac mitochondria. II. Formation of superoxide anion, hydrogen peroxide, and hydroxyl radical. J Biol Chem. 1986;261:3068–74.

  38. 38.

    Yen HC, Oberley TD, Vichitbandha S, Ho YS, Clair DKS. The protective role of manganese superoxide dismutase against adriamycin-induced acute cardiac toxicity in transgenic mice. J Clin Invest. 1996;98:1253–60.

  39. 39.

    Biesalski HK, Frank J. Antioxidants in cancer therapy: is there a rationale to recommend antioxidants during cancer therapy? Biofactors. 2003;17:229–40.

  40. 40.

    Conklin KA. Cancer chemotherapy and antioxidants. J Nutr. 2004;134:3201–4.

  41. 41.

    Muralikrishnan G, Amanullah S, Basha MI, Boopalan S, Vijayakumar S, Shakeel F. Effect of vitamin C on lipidperoxidation and antioxidant status in tamoxifen-treated breast cancer patients. Chemotherapy. 2010;56:298–302.

Download references

Acknowledgements

This study was supported by the National Nature Science Foundation of China (81374054, 81573559, 81530098), the Nature Science Foundation of Jiangsu province (BK20171395), and the outstanding youth fund of State Key Laboratory of Natural Medicines (SKLNMZZJQ201602).

Author information

YL and GJW designed the studies; BYS, CC, YFX, JJS, HMG, HFL, XNL, DK, YHS, ZPZ, and XXY performed the research; BYS and CC analyzed data; and YL wrote the paper.

Correspondence to Guang-ji Wang or Yan Liang.

Ethics declarations

Conflict of interest

We declare that we have no financial and personal relationships with other people or organizations that can inappropriately influence our work, there is no professional or other personal interest of any nature or kind in any product, service and/or company that could be construed as influencing the position presented in, or the review of, the manuscript entitled.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Shen, B., Chen, C., Xu, Y. et al. Is the combinational administration of doxorubicin and glutathione a reasonable proposal?. Acta Pharmacol Sin 40, 699–709 (2019). https://doi.org/10.1038/s41401-018-0158-8

Download citation

Keywords

  • doxorubicin
  • glutathione
  • cardioprotection
  • hepatoprotection
  • chemotherapeutic efficacy
  • antioxidants

Further reading